CD4 and Huntington disease: As such, Lisowska et al. performed a study to explore the effects of rhEPO on CD4+ lymphocytes from HD patients and found that rhEPO normalized the proliferative ability and activation markers of CD4+ lymphocytes, including CD28 and CD6946.